At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 46 enrolled
Drug / intervention
PG-11047drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study of CGC-11047 in Subjects With Advanced Refractory Solid Tumors
In Brief
A Phase 1 clinical trial evaluating PG-11047 for Cancer. Completed, enrolled 46 participants across 1 site.
Detailed Summary
This phase I study aims to assess the safety and tolerability of a new drug - PG-11047 - and to establish what happens to the drug once inside the body. An escalating dose of PG-11047 will be investigated in this study and the maximum tolerated dose of the drug will be established.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2005
First PostedJun 2008
Primary CompletionAug 2009
TodayJul 2026
First PostedJun 26, 2008
Enrollment StartMar 1, 2005
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 18.0 years ago
Interventions
PG-11047drug
PG-11047 will be administered as a 60-minute intravenous infusion on days 1, 8 and 15 of each 28 day cycle. A treatment cycle will be defined as 4 weeks of therapy. The planned minimum treatment schedule is 2 cycles of PG-11047 treatment (8 weeks).